EGFR and non-small cell lung carcinoma: In a previous study, the combination of DCA with the first-generation EGFR-TKIs erlotinib and gefitinib dramatically reduced the viability of EGFR-mutant NSCLC cells (NCI-H1975 and NCI-H1650) [110].